HK1220386A1 - 受體拮抗劑在軟骨疾病的治療中的用途 - Google Patents
受體拮抗劑在軟骨疾病的治療中的用途Info
- Publication number
- HK1220386A1 HK1220386A1 HK16108526.8A HK16108526A HK1220386A1 HK 1220386 A1 HK1220386 A1 HK 1220386A1 HK 16108526 A HK16108526 A HK 16108526A HK 1220386 A1 HK1220386 A1 HK 1220386A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment
- receptor antagonists
- cartilage disease
- cartilage
- disease
- Prior art date
Links
- 101150109738 Ptger4 gene Proteins 0.000 title 1
- 208000015100 cartilage disease Diseases 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013057180 | 2013-03-19 | ||
| PCT/JP2014/001597 WO2014148053A1 (en) | 2013-03-19 | 2014-03-19 | Use of ep4 receptor antagonists in the treatment of cartilage disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1220386A1 true HK1220386A1 (zh) | 2017-05-05 |
Family
ID=51579750
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16100089.4A HK1212211A1 (zh) | 2013-03-19 | 2016-01-06 | 受體拮抗劑在軟骨疾病的治療中的用途 |
| HK16108526.8A HK1220386A1 (zh) | 2013-03-19 | 2016-07-19 | 受體拮抗劑在軟骨疾病的治療中的用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16100089.4A HK1212211A1 (zh) | 2013-03-19 | 2016-01-06 | 受體拮抗劑在軟骨疾病的治療中的用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160317514A1 (zh) |
| EP (1) | EP2976105B1 (zh) |
| JP (1) | JP6340702B2 (zh) |
| KR (3) | KR102239641B1 (zh) |
| CN (2) | CN107496421A (zh) |
| BR (1) | BR112015023663A2 (zh) |
| CA (1) | CA2907049C (zh) |
| ES (1) | ES2938840T3 (zh) |
| HK (2) | HK1212211A1 (zh) |
| MX (1) | MX2015013328A (zh) |
| RU (1) | RU2663620C2 (zh) |
| WO (1) | WO2014148053A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6419857B2 (ja) | 2014-03-06 | 2018-11-07 | アラタナ セラピューティクス、 インコーポレイテッド | グラピプラント組成物およびその使用方法 |
| JP2021522211A (ja) | 2018-04-16 | 2021-08-30 | アリーズ セラピューティクス， インコーポレイテッド | Ｅｐ４阻害剤およびその使用 |
| WO2019245590A1 (en) | 2018-06-18 | 2019-12-26 | Avista Pharma Solutions, Inc. | Chemical compounds |
| CA3115472A1 (en) | 2018-10-05 | 2020-04-09 | Annapurna Bio, Inc. | Compounds and compositions for treating conditions associated with apj receptor activity |
| CA3128346A1 (en) | 2019-01-30 | 2020-08-06 | Avista Pharma Solutions, Inc. | Synthetic process and novel intermediates |
| US11459331B2 (en) | 2019-01-30 | 2022-10-04 | Avista Pharma Solutions, Inc. | Chemical compounds |
| CN114262301A (zh) * | 2020-09-16 | 2022-04-01 | 华东师范大学 | 靶向ep4受体小分子拮抗剂及其在骨关节炎、软骨缺损治疗中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843959A (en) * | 1997-03-19 | 1998-12-01 | University Of Florida Research Foundation, Inc. | Methods and bicyclic polyamine compositions for the treatment of inflammation |
| HN2001000224A (es) * | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| WO2004067524A1 (en) | 2003-01-29 | 2004-08-12 | Pharmagene Laboratories Limited | Ep4 receptor antagonists |
| BRPI0414130B8 (pt) * | 2003-09-03 | 2021-05-25 | Askat Inc | compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem. |
| CN1946391A (zh) * | 2004-04-20 | 2007-04-11 | 辉瑞产品公司 | 包含α－2－δ配体的组合 |
| WO2005105732A1 (en) * | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Substituted methyl aryl or heteroaryl amide compounds |
| CA2600510C (en) * | 2005-03-11 | 2010-11-02 | Pfizer Inc. | Crystal forms of an imidazole derivative |
| CA2660133C (en) * | 2006-08-11 | 2015-10-27 | Merck Frosst Canada Ltd. | Thiophenecarboxamide derivatives as ep4 receptor ligands |
| WO2011124524A1 (de) * | 2010-04-08 | 2011-10-13 | Boehringer Ingelheim International Gmbh | Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten |
-
2014
- 2014-03-19 EP EP14768803.0A patent/EP2976105B1/en active Active
- 2014-03-19 WO PCT/JP2014/001597 patent/WO2014148053A1/en active Application Filing
- 2014-03-19 KR KR1020207024372A patent/KR102239641B1/ko active IP Right Grant
- 2014-03-19 MX MX2015013328A patent/MX2015013328A/es active IP Right Grant
- 2014-03-19 US US14/777,610 patent/US20160317514A1/en not_active Abandoned
- 2014-03-19 RU RU2015144676A patent/RU2663620C2/ru active
- 2014-03-19 BR BR112015023663-4A patent/BR112015023663A2/pt not_active Application Discontinuation
- 2014-03-19 CN CN201710863043.6A patent/CN107496421A/zh active Pending
- 2014-03-19 ES ES14768803T patent/ES2938840T3/es active Active
- 2014-03-19 CA CA2907049A patent/CA2907049C/en active Active
- 2014-03-19 KR KR1020157027976A patent/KR20150130404A/ko not_active IP Right Cessation
- 2014-03-19 KR KR1020217012435A patent/KR102556734B1/ko active IP Right Grant
- 2014-03-19 JP JP2015545594A patent/JP6340702B2/ja active Active
- 2014-03-19 CN CN201480017059.XA patent/CN105163761B/zh active Active
-
2016
- 2016-01-06 HK HK16100089.4A patent/HK1212211A1/zh unknown
- 2016-07-19 HK HK16108526.8A patent/HK1220386A1/zh unknown
-
2017
- 2017-08-04 US US15/669,031 patent/US10786490B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160317514A1 (en) | 2016-11-03 |
| ES2938840T3 (es) | 2023-04-17 |
| CN105163761A (zh) | 2015-12-16 |
| RU2663620C2 (ru) | 2018-08-07 |
| KR102239641B1 (ko) | 2021-04-13 |
| KR20200102558A (ko) | 2020-08-31 |
| HK1212211A1 (zh) | 2016-06-10 |
| RU2015144676A (ru) | 2017-05-03 |
| EP2976105A1 (en) | 2016-01-27 |
| BR112015023663A2 (pt) | 2020-10-20 |
| CA2907049C (en) | 2021-08-10 |
| EP2976105B1 (en) | 2023-01-04 |
| JP6340702B2 (ja) | 2018-06-13 |
| US20170360764A1 (en) | 2017-12-21 |
| CA2907049A1 (en) | 2014-09-25 |
| WO2014148053A1 (en) | 2014-09-25 |
| US10786490B2 (en) | 2020-09-29 |
| KR20210048606A (ko) | 2021-05-03 |
| MX2015013328A (es) | 2016-02-26 |
| KR102556734B1 (ko) | 2023-07-18 |
| CN107496421A (zh) | 2017-12-22 |
| CN105163761B (zh) | 2018-12-21 |
| JP2016515507A (ja) | 2016-05-30 |
| EP2976105A4 (en) | 2016-11-23 |
| KR20150130404A (ko) | 2015-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202012656WA (en) | Heterocyclic compounds useful in the treatment of disease | |
| IL267066B (en) | Activin-actrii antagonists and their use for the treatment of bone and other disorders | |
| HK1249401A1 (zh) | Ep-4受體拮抗劑在治療il-23介導疾病中的用途 | |
| IL241184A0 (en) | Naphthyridine derivatives and their use as antagonists of alpha-v-beta-6-integrins | |
| SG11201600707QA (en) | Substituted aminopyrimidine compounds and methods of use | |
| GB201320729D0 (en) | Therapeutic compounds and their use | |
| HK1220386A1 (zh) | 受體拮抗劑在軟骨疾病的治療中的用途 | |
| HK1216890A1 (zh) | 苄基-取代的吡唑並吡啶及其用途 | |
| HRP20181536T1 (hr) | Supstituirani piperidinil-tetrahidrokinolini i njihova uporaba kao antagonisti alfa-2c adrenoreceptora | |
| HK1212965A1 (zh) | -丙- -炔基甲酰胺衍生物及其作為 拮抗劑的用途 | |
| GB201311361D0 (en) | Compounds and their therapeutic use | |
| GB201308736D0 (en) | Compounds and their therapeutic use | |
| GB201321089D0 (en) | Leukotriene receptor antagonists and their derivatives for use as antibacterial agents | |
| GB201603588D0 (en) | Use of nanoparticles in cleaning well bores | |
| GB201317804D0 (en) | Therapeutic compounds and their use | |
| GB201316173D0 (en) | Compounds and their therapeutic use | |
| GB201307677D0 (en) | Compounds and their therapeutic use |